Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14

SAN DIEGO, March 8, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will report fourth quarter and full year 2011 financial results after the NASDAQ Global Select Market closes on Wednesday, March 14, 2012. That same afternoon, Arena's President and Chief Executive Officer, Jack Lief, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results for the fourth quarter and full year 2011 and to provide a business and financial update.

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Fourth Quarter and Full Year 2011 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena has submitted regulatory applications for US and EU approval of its most advanced drug candidate, which is intended for weight management, and the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 27, 2012.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication, regulatory review and potential approval of Arena's most advanced drug candidate, lorcaserin; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review is uncertain and Arena's applications for regulatory approval of lorcaserin may not be reviewed when anticipated; the EU application is subject to acceptance and confirmation by the EU regulatory agency that it is sufficiently complete to permit a substantive review; the FDA may not complete its review of the lorcaserin application by the PDUFA date; the occurrence, timing and results of FDA advisory committee meetings relating to lorcaserin and other drug candidates; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review or approval; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena Pharmaceuticals, Inc. Robert E. Hoffman, Vice President, Finance and Chief Financial Officer 858.453.7200  Investor Contact: Russo Partners, LLC

Media Contact: Russo Partners, LLCCindy McGee, Vice President

David Schull, President







SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
2. Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
3. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
4. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
6. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
7. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
8. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
9. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
10. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
11. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
Post Your Comments:
(Date:10/12/2015)... CINCINNATI , Oct. 12, 2015 A ... hearing impaired children can predict whether they will develop ... surgery, according to a study in the journal ... --> In the journal,s Oct. 12 ... say their computer program determines how specific regions of ...
(Date:10/12/2015)... Oct. 12, 2015 CorVascular Diagnostics, ... medical technology company that designs and distributes ... it has entered into a collaboration and ... dedicated to producing devices, software and services ... PAD-IQ®, developed and produced by Vasamed, provides ...
(Date:10/12/2015)... PUNE, India , October 12, 2015 /PRNewswire/ ... The Plague - Pipeline Review, H2 2015 ... helps strengthen plague R&D pipelines by identifying new ... products. . --> ... report on Plague pipeline spread across 62 pages, ...
Breaking Medicine Technology:
(Date:10/12/2015)... Angeles, CA (PRWEB) , ... October 12, 2015 ... ... on August 19, 2015, high school aged female athletes, particularly in ... developing potentially sidelining repetitive motion and mechanical overuse injuries than male peers in ...
(Date:10/12/2015)... ... 2015 , ... According to an article published September 27th by ... way to save money on the healthcare needs of patients across the country. Especially ... call visits can often effectively eliminate the need to go in and out of ...
(Date:10/12/2015)... ... October 12, 2015 , ... According to an article ... of San Antonio, Texas recommended that any high-rises in the city limits that do ... going forward. The article explains that it wasn’t until 1982 that the city started ...
(Date:10/12/2015)... ... 12, 2015 , ... The Horizon Foundation for New Jersey has awarded $846,600 ... and enhancing the quality of life in the Garden State. The grants, representing the ... , The charitable arm of Horizon Blue Cross Blue Shield of New Jersey, ...
(Date:10/12/2015)... ... October 12, 2015 , ... AcousticSheep LLC, creators of ... in honor of Breast Cancer Awareness Month. During the month of October, ... a SleepPhones® Classic product to a breast cancer patient at the Cleveland Clinic. ...
Breaking Medicine News(10 mins):